As part of the PRACTIS Program, PD Dr. Kamp was relieved of his clinical duties in the Department of Pneumology and Infectiology for 18 months. He used this time to conduct research in the Lung Research Group at the Institute of Pathology at MHH. His research primarily focused on alveolar capillary dysplasia (ACD), a rare cause of persistent pulmonary hypertension in newborns (PPHN), and the pathophysiology of severe COVID-19. In this context, Dr. Kamp and his team demonstrated the occurrence of a special form of blood vessel formation known as intussusceptive angiogenesis, which significantly contributes to subsequent fibrotic remodeling of lung tissue.

This research opens up promising prospects for advancing therapeutic approaches. Dr. Kamp has been recognized with the 2024 Graduate Scholarship by the Novartis Foundation for Therapeutic Research as a result. “This award is a tremendous recognition of my previous work and simultaneously an incentive to continue seeking innovative solutions for the diagnosis and treatment of lung diseases,” emphasized Dr. Kamp, who has been co-leading the Lung Research Group with Dr. Lavinia Neubert since September 1, 2022. The scholarship, endowed with €4,000 by the Novartis Foundation, is supplemented by an additional €4,000 through the PRACTIS Program at MHH. “We are very pleased about the additional research funding, which will enable us to implement new ideas,” said Dr. Kamp, looking ahead to many further projects that will be carried out at BREATH in the future.

We at BREATH warmly congratulate Dr. Kamp on this outstanding achievement and are proud to have him in our ranks. We are confident that his research will make a significant contribution to improving treatment options for patients with chronic lung diseases.

Text: BREATH/AB

Photo. private